{"entity":{"id":"chris-parker","kind":"person","name":"Chris C. Parker","aka":[],"tldr":"London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.","summary":"Chris Parker is a clinical oncologist at The Royal Marsden and The Institute of Cancer Research. He was first author of the 2013 New England Journal of Medicine report of ALSYMPCA, in which the alpha-emitter radium-223 improved overall survival in castration-resistant prostate cancer with bone metastases, and of the 2020 Lancet report of RADICALS-RT, which found that early salvage radiotherapy on PSA rise was as good as adjuvant radiotherapy after prostatectomy, with less toxicity.","asOf":"2026-09-18","links":[],"tags":["prostate","radiotherapy","trialist"],"related":[],"cancers":["prostate-mcrpc","prostate-bcr","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-radicals-rt-lancet-2020","paper-alsympca-radium-223-nejm-2013"],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical oncologist, The Royal Marsden and The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Prostate radiotherapy","Radium-223","Post-prostatectomy radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parker%5BAuthor%5D"}],"papers":[]},"route":"/people/chris-parker/","neighbours":{"cancer":[{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"institution":[{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"paper":[{"id":"paper-alsympca-radium-223-nejm-2013","kind":"paper","name":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","route":"/key-papers/paper-alsympca-radium-223-nejm-2013/"},{"id":"paper-radicals-rt-lancet-2020","kind":"paper","name":"RADICALS-RT: timing of radiotherapy after radical prostatectomy","route":"/key-papers/paper-radicals-rt-lancet-2020/"}]}}